UAWJ248 

UAWJ248 is a SARS-CoV-2 main protease (M^pro) inhibitor with an IC₅₀ of 0.012 μM. UAWJ248 inhibits activity via initial reversible binding followed by irreversible inactivation. UAWJ248 inhibits SARS-CoV-2 replication and can be used for the research of SARS-CoV-2 infection^[1].

UAWJ248 potently inhibits tag-free native SARS-CoV-2 M^pro with an IC₅₀ of 0.012 µM and shows IC₅₀ >20 μM for PL^pro[1].
UAWJ248 (0.01-100 µM; 48 h) inhibits SARS-CoV-2 replication in Vero E6 cells with an EC₅₀ of 20.49 µM^[1].
UAWJ248 (0.01-100 µM) inhibits SARS-CoV-2 replication in Vero E6 cells with an EC₅₀ of 11.1 µM in the plaque assay^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

599.72

C₃₁H₄₅N₅O₇

2589736-94-5

O=C(NCC1)[C@@H]1C[C@@H](C(C(NC2CC2)=O)=O)NC([C@H](CC(C)C)NC([C@H](CC(C)C)NC(OCC3=CC=CC=C3)=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Sacco MD, et al. Structure and inhibition of the SARS-CoV-2 main protease reveals strategy for developing dual inhibitors against Mpro and cathepsin L. bioRxiv [Preprint]. 2020 Jul 27:2020.07.27.223727.  [Content Brief]